M. Kathleen Behrens

Dr. Behrens also serves as a member and Chair of the Board of Directors of Sarepta Therapeutics, a medical research and drug development company, and is also Chairperson of its Audit Committee and a member of its Research and Development Committee. She is also a member and Chair of the Board of Directors of MiMedx Group, a wound care company, as well as a member of its Compliance and Ethics Committee. Dr. Behrens served on the Board of Directors of Amylin Pharmaceuticals, a biotechnology company, from June 2009 until its sale to Bristol-Myers Squibb in 2012. From 1983 to 1996, she served as a General Partner and Managing Director at Robertson Stephens & Co., an investment bank focused on technology companies. From 1996 to 2009, Dr. Behrens continued in her capacity as a general partner for selected venture funds for RS Investments, an investment management and research firm, after management led a buyout of RS Investments from Bank of America. While at RS Investments, she served as a Managing Director from 1996 to 2002, and as a consultant from 2003 to 2009. She served as a member of the President’s Council of Advisors on Science and Technology (PCAST) from 2001 to early 2009 and as Chairwoman of its subcommittee on Personalized Medicine. Dr. Behrens also served as a Director of Science, Technology and Economic Policy for the National Research Council and as a Director, President and Chairwoman of the National Venture Capital Association. Dr. Behrens received a B.S. in Biological Sciences and a Ph.D. in Microbiology from the University of California, Davis.